RARE vs. PRGO, ARWR, MRTX, ACAD, BHC, UTHR, VTRS, SRPT, RDY, and INSM
Should you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Perrigo (PRGO), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), United Therapeutics (UTHR), Viatris (VTRS), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), and Insmed (INSM). These companies are all part of the "pharmaceutical preparations" industry.
Ultragenyx Pharmaceutical (NASDAQ:RARE) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, community ranking, institutional ownership, dividends, profitability and earnings.
Ultragenyx Pharmaceutical has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.
Perrigo has higher revenue and earnings than Ultragenyx Pharmaceutical. Perrigo is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 5.8% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 0.7% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Ultragenyx Pharmaceutical had 7 more articles in the media than Perrigo. MarketBeat recorded 15 mentions for Ultragenyx Pharmaceutical and 8 mentions for Perrigo. Ultragenyx Pharmaceutical's average media sentiment score of 0.55 beat Perrigo's score of 0.27 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.
Ultragenyx Pharmaceutical currently has a consensus target price of $86.50, suggesting a potential upside of 92.82%. Perrigo has a consensus target price of $39.33, suggesting a potential upside of 39.93%. Given Ultragenyx Pharmaceutical's higher possible upside, equities analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Perrigo.
Perrigo has a net margin of -0.17% compared to Ultragenyx Pharmaceutical's net margin of -138.58%. Perrigo's return on equity of 6.96% beat Ultragenyx Pharmaceutical's return on equity.
Ultragenyx Pharmaceutical received 48 more outperform votes than Perrigo when rated by MarketBeat users. Likewise, 77.16% of users gave Ultragenyx Pharmaceutical an outperform vote while only 66.72% of users gave Perrigo an outperform vote.
Summary
Ultragenyx Pharmaceutical beats Perrigo on 11 of the 18 factors compared between the two stocks.
Get Ultragenyx Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ultragenyx Pharmaceutical Competitors List
Related Companies and Tools
